217 related articles for article (PubMed ID: 28797648)
21. Screening for genes associated with ovarian cancer prognosis.
Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas.
Fraile JM; Ordóñez GR; Quirós PM; Astudillo A; Galván JA; Colomer D; López-Otín C; Freije JM; Puente XS
Oncotarget; 2013 Nov; 4(11):1919-32. PubMed ID: 24243807
[TBL] [Abstract][Full Text] [Related]
23. A snapshot of the Ixodes scapularis degradome.
Mulenga A; Erikson K
Gene; 2011 Aug; 482(1-2):78-93. PubMed ID: 21596113
[TBL] [Abstract][Full Text] [Related]
24. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
25. The Degradome database: mammalian proteases and diseases of proteolysis.
Quesada V; Ordóñez GR; Sánchez LM; Puente XS; López-Otín C
Nucleic Acids Res; 2009 Jan; 37(Database issue):D239-43. PubMed ID: 18776217
[TBL] [Abstract][Full Text] [Related]
26. Proteolytic control of regulated necrosis.
Fuchslocher Chico J; Saggau C; Adam D
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2147-2161. PubMed ID: 28577894
[TBL] [Abstract][Full Text] [Related]
27. Gene-expression profiling in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Cannistra SA
Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
[TBL] [Abstract][Full Text] [Related]
28. Data-mining of the Meloidogyne incognita degradome and comparative analysis of proteases in nematodes.
Castagnone-Sereno P; Deleury E; Danchin EG; Perfus-Barbeoch L; Abad P
Genomics; 2011 Jan; 97(1):29-36. PubMed ID: 20951198
[TBL] [Abstract][Full Text] [Related]
29. [Monitoring novel ovarian carcinoma associated genes using cDNA expression microarray].
Chang XH; Cheng YX; Zhang XY; Cui H; Feng J
Zhonghua Fu Chan Ke Za Zhi; 2003 Jun; 38(6):322-4. PubMed ID: 12895369
[TBL] [Abstract][Full Text] [Related]
30. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.
Shahinian H; Loessner D; Biniossek ML; Kizhakkedathu JN; Clements JA; Magdolen V; Schilling O
Mol Oncol; 2014 Feb; 8(1):68-82. PubMed ID: 24120346
[TBL] [Abstract][Full Text] [Related]
31. Microarray-based gene expression studies in ovarian cancer.
Chon HS; Lancaster JM
Cancer Control; 2011 Jan; 18(1):8-15. PubMed ID: 21273975
[TBL] [Abstract][Full Text] [Related]
32. Rhomboid proteases in human disease: Mechanisms and future prospects.
Düsterhöft S; Künzel U; Freeman M
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2200-2209. PubMed ID: 28460881
[TBL] [Abstract][Full Text] [Related]
33. A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response.
Busuttil RA; George J; Tothill RW; Ioculano K; Kowalczyk A; Mitchell C; Lade S; Tan P; Haviv I; Boussioutas A
Clin Cancer Res; 2014 May; 20(10):2761-72. PubMed ID: 24658156
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide identification and structure-function studies of proteases and protease inhibitors in Cicer arietinum (chickpea).
Sharma R; Suresh CG
Comput Biol Med; 2015 Jan; 56():67-81. PubMed ID: 25464349
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profile differences in high and low metastatic human ovarian cancer cell lines by gene chip.
Xu S; Mou H; Lü G; Zhu C; Yang Z; Gao Y; Lou H; Liu X; Cheng Y; Yang W
Chin Med J (Engl); 2002 Jan; 115(1):36-41. PubMed ID: 11930655
[TBL] [Abstract][Full Text] [Related]
37. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
Grisaru-Granovsky S; Salah Z; Maoz M; Pruss D; Beller U; Bar-Shavit R
Int J Cancer; 2005 Jan; 113(3):372-8. PubMed ID: 15455382
[TBL] [Abstract][Full Text] [Related]
39. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Ruciński M; Zabel M
Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
[TBL] [Abstract][Full Text] [Related]
40. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.
Welsh JB; Zarrinkar PP; Sapinoso LM; Kern SG; Behling CA; Monk BJ; Lockhart DJ; Burger RA; Hampton GM
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1176-81. PubMed ID: 11158614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
